Pipeline

SH-105

A treatment for Breast & Ovarian cancer

Disease state overview

SH-105 is well established for the treatment of cancer in adults, as evidenced by ongoing use across multiple indications:

  • Breast cancer​ (approximately 339,250 patients in the US diagnosed per year)1
  • Ovarian cancer (approximately 19,880 patients in the US diagnosed per year)1

Regulatory Status

Shorla Oncology have successfully completed the filing of our New Drug Application (‘NDA’) with the US Health Authority, the Food and Drug Administration (‘FDA’) on our oncology drug SH-105. This positive step strengthens our efforts to bring SH-105 to market benefiting women suffering from breast and ovarian cancer. A significant milestone on Shorla Oncology’s journey of bringing innovative oncology products to market.

1 American Cancer Society. Cancer Facts & Figures, 2021.